Crescendo | GenomeWeb

Crescendo

The studies looked at applications including predicting disease progression, guiding drug tapering, and identifying patients at risk of related conditions.

The company presented new data at a meeting last week showing that Vectra DA predicted whether patients would do better on one or the other of two possible second-line therapies.

As it tries to kick-start stalled revenue growth, the company must work to convince doctors the test offers benefits beyond standard of care.

Crescendo Bioscience's Vectra DA test predicts progressive joint damage in rheumatoid arthritis patients better than other clinical markers of disease activity in new study cohort.

NEW YORK (GenomeWeb) — Data presented earlier this month at the 2014 European League Against Rheumatism (EULAR) Annual Congress by Crescendo Bioscience has added upon earlier retrospective data supporting the clinical utility of the company's Vectra DA test in measuring disease activity and predi

With Myriad Genetics' announcement this week that it will acquire Crescendo Bioscience for $270 million in cash, clinical proteomics has scored what is perhaps its most significant endorsement to date.

NEW YORK (GenomeWeb News) – Myriad Genetics said after the close of the market Tuesday that it has signed a definitive agreement to acquire Crescendo Bioscience for $270 million in cash, though the amount Myriad will pay will be reduced by $25 million for repayment of a loan it previously made to

NEW YORK (GenomeWeb News) – Myriad Genetics has informed Crescedo Bioscience of its “preliminary, non-binding interest” in acquiring the company, Myriad said in a regulatory document today.

Researchers presenting data on Crescendo Bioscience's Vectra DA test at the American College of Rheumatology annual meeting late last month shared a number of studies supporting the potential of the test not just for disease monitoring, but also to predict patients' risk of joint

Crescendo Garners Medicare Coverage for Vectra DA
Medicare contractor Palmetto GBA has agreed to reimburse for Crescendo Bioscience's Vectra DA multi-marker molecular diagnostic that assesses rheumatoid arthritis activity.

Pages

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.